WO2023150696A3 - Compositions and methods for delivering hydrophobic bioactive agents - Google Patents

Compositions and methods for delivering hydrophobic bioactive agents Download PDF

Info

Publication number
WO2023150696A3
WO2023150696A3 PCT/US2023/061962 US2023061962W WO2023150696A3 WO 2023150696 A3 WO2023150696 A3 WO 2023150696A3 US 2023061962 W US2023061962 W US 2023061962W WO 2023150696 A3 WO2023150696 A3 WO 2023150696A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
bioactive agents
hydrophobic bioactive
delivering hydrophobic
Prior art date
Application number
PCT/US2023/061962
Other languages
French (fr)
Other versions
WO2023150696A9 (en
WO2023150696A2 (en
Inventor
Timothy GEISTLINGER
Janine Lin
Vaibhav Bhatt
Original Assignee
Perfect Day, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perfect Day, Inc. filed Critical Perfect Day, Inc.
Publication of WO2023150696A2 publication Critical patent/WO2023150696A2/en
Publication of WO2023150696A3 publication Critical patent/WO2023150696A3/en
Publication of WO2023150696A9 publication Critical patent/WO2023150696A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717—Plasma globulins, lactoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided is a recombinant milk protein for delivery of a hydrophobic bioactive agent, a composition comprising such recombinant milk protein, and a method for using such composition.
PCT/US2023/061962 2022-02-03 2023-02-03 Compositions and methods for delivering hydrophobic bioactive agents WO2023150696A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263306423P 2022-02-03 2022-02-03
US63/306,423 2022-02-03

Publications (3)

Publication Number Publication Date
WO2023150696A2 WO2023150696A2 (en) 2023-08-10
WO2023150696A3 true WO2023150696A3 (en) 2023-09-28
WO2023150696A9 WO2023150696A9 (en) 2024-04-04

Family

ID=87552978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/061962 WO2023150696A2 (en) 2022-02-03 2023-02-03 Compositions and methods for delivering hydrophobic bioactive agents

Country Status (1)

Country Link
WO (1) WO2023150696A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021168343A2 (en) * 2020-02-19 2021-08-26 Perfect Day, Inc. Hypoallergenic recombinant milk proteins and compositions comprising the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021168343A2 (en) * 2020-02-19 2021-08-26 Perfect Day, Inc. Hypoallergenic recombinant milk proteins and compositions comprising the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAHERI-KAFRANI ET AL.: "beta-Lactoglobulin mutant Lys69Asn has attenuated IgE and increased retinol binding activity", JOURNAL OF BIOTECHNOLOGY, vol. 212, 2015, pages 181 - 188, XP029284011, DOI: 10.1016/j.jbiotec.2015.08.006 *

Also Published As

Publication number Publication date
WO2023150696A9 (en) 2024-04-04
WO2023150696A2 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
Yamamoto et al. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells
CR20210489A (en) Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection
WO2019035057A3 (en) Exosomes for target specific delivery and methods for preparing and delivering the same
PH12021551279A1 (en) Modified amine lipids
WO2022035911A4 (en) Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
ZA200504804B (en) Topical anti-infective formulations
MXPA05012278A (en) Compositions for delivering peptide yy and pyy agonists.
WO2020097511A3 (en) Messenger rna therapy for treatment of ocular diseases
WO2021007341A3 (en) Live biotherapeutic compositions and methods
WO2023150696A3 (en) Compositions and methods for delivering hydrophobic bioactive agents
WO2021158854A3 (en) Large gene vectors and delivery and uses thereof
MX2022006949A (en) Compositions and methods for treating leber's hereditary optic neuropathy with nadh dehydrogenase proteins.
EA202091464A1 (en) COMPOSITIONS FOR TREATMENT OF NON-ALCOHOLIC FAT LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS
MX2020013772A (en) Compositions and methods for treating leber's hereditary optic neuropathy.
MX2021004551A (en) Pharmaceutical composition for treating aplastic anemia.
EP3925617A4 (en) Recombinant protein for eliminating boar taint and vaccine composition comprising same
JOP20210152A1 (en) Protein solution formulation containing high concentration of an anti-vegf antibody
MX2023002288A (en) Protein secretion inhibitors.
EP3994151A4 (en) Novel peptide, compositions and method for delivery of agents into cells and tissues
AU2022901069A0 (en) Compounds, compositions and methods for delivery of biologically active agents
MX2021015694A (en) Composition and methods for stabilizing liquid protein formulations.
MX2022008655A (en) Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components.
WO2023154841A3 (en) Sars-cov-2 neutralizing synthetic proteins
WO2023225619A3 (en) Delivery of focal adhesion kinase for treating vascular and/or capillary tissue injury
MX2022013550A (en) Compositions and methods for delivering pharmaceutically active agents.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23750449

Country of ref document: EP

Kind code of ref document: A2